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A B S T R A C T
This review focuses on the Cbl-b muscle atrophy-associated ubiquitin ligase and its inhibitors. Herein, the role of
E3 ubiquitin ligase-associated muscle atrophy genes (atrogenes), including MAFbx-1/agrogin-1 and MuRF-1, as
well as another ubiquitin ligase, Cbl-b and its inhibitors, is discussed. Cbl-b plays an important role in unloading
muscle atrophy caused by spaceflight and in bedridden patients: Cbl-b ubiquitinated and induced the de-
gradation of IRS-1, a key intermediate in the IGF-1 signaling. Furthermore, a pentapetpide (DGpYMP), inhibited
Cbl-b-mediated IRS-1 ubiquitination. This peptide-based Cbl-b inhibitor Cblin and its homologous peptides in
foods presumably affect muscle atrophy under such conditions.
1. Introduction
Skeletal muscles are the most susceptible organs to the activity of
the musculature (mechanical stress) and can vary in volume depending
on the degree of physical activity. A marked decrease in muscle mass as
a result of unloading, such as during spaceflight or in bedridden in-
dividuals, is known as disuse muscle atrophy. We collaborated with
Japan Aerospace Exploration Agency (JAXA) to study the changes in
atrophied skeletal muscle using the skeletal muscle of rats that had been
in space for 2 weeks [1].
The pathways that degrade skeletal muscle constituent proteins
include the lysosomal pathway of cathepsins, a calcium-dependent
pathway by calpain, and the proteasome pathway, which degrades
ubiquitinated proteins. Increased proteasome activity, enhanced ubi-
quitin expression, and the accumulation of ubiquitinated proteins were
observed in skeletal muscles atrophied by spaceflight [1,2], suggesting
that the ubiquitin-proteasome protein degradation pathway plays a
fundamental role. Briefly, the ubiquitin-proteasome proteolysis
pathway consists of the ubiquitination system and 26S proteasome. The
ubiquitination system consists of a group of ubiquitin activating en-
zymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases
(E3). The 26S proteasome degrades polyubiquitinated substrates in the
ubiquitination system (Fig. 1). The expression of ubiquitin ligase, which
determines the specificity of the substrate, is the rate-limiting step in
this proteolytic pathway. Our comprehensive analysis of ubiquitin li-
gase expression revealed that Casitas B-lineage lymphoma-b (Cbl-b),
muscle RING-finger protein-1 (MuRF-1), Siah-1, and muscle atrophy F-
box-1 (MAFbx-1)/atrogin-1 were highly elevated in the atrophied ske-
letal muscle of the space-flown rats [2]. However, the chip MAFbx-1/
atrogin-1 was not used at the time. An analysis of MAFbx-1/atrogin-1
after the publication of the paper showed an approximately 20-fold
increase in expression [3,4]. In the first half of this review, muscle
atrophy-associated ubiquitin ligases (atrogenes) MAFbx-1/atrogin-1
and MuRF-1 are introduced.
In a previous study, Cbl-b was identified as an upregulated ubiquitin
ligase that induces muscle protein degradation [2,5,6]. Cblin, a peptide-
based Cbl-b inhibitor, and its N-myristoylated form, suppresses the
ubiquitination of insulin receptor substrate-1 (IRS-1), a key adapter
protein in insulin-like growth factor-1 (IGF-1) signaling [5,7]. A search
for the amino acid sequence of the Cblin peptide in the food protein
database resulted in the identification of soy glycinin [8]. In the second
half of this review, we describe the effects of the Cblin peptide and
Cblin-like peptide in soy glycinin on IRS-1 ubiquitination by Cbl-b.
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2. Muscle atrophy-associated ubiquitin ligases (atrogenes)
The muscle atrophy genes (atrogenes) MuRF-1 and MAFbx-1/
atrogin-1 were identified using the DNA microarray method [3,4].
These genes are part of a group of ubiquitin ligases specific to skeletal
muscle and myocardium whose expression increases when the sciatic
nerve is resected. Mice with knockouts of these genes are resistant to
muscular atrophy due to sciatic nerve resection. The most potent
trophic factor for muscle cells is IGF-1. When not present in a muscle
atrophy environment, IGF-1 signaling is sufficient to activate muscle
protein synthesis and suppress muscle protein degradation [9]. How-
ever, under muscle atrophy conditions, IGF-1 signaling is attenuated
and Akt-1 activation (phosphorylation) is impaired, resulting in de-
creased muscle protein synthesis and, conversely, increased muscle
protein degradation. Interestingly, the muscle proteolysis and expres-
sion of both these atrogenes are regulated by the fork-head box O
(FOXO) transcription factor downstream of Akt-1. In other words, when
Akt-1 activation decreases, unphosphorylated FOXO transcription fac-
tors translocate into the nucleus and increase atrogene transcription.
As shown in Fig. 1, ubiquitin ligase is composed of homologous to
the E6-AP c-terminus (HECT), U-box, really interesting new gene
(RING), and the Skp1-cullin-F-box (SCF) complex. MAFbx-1/atrogin-1
is a SCF complex-type ubiquitin ligase. SCF complex-type ubiquitin li-
gases use cullin as a platform protein. The RING domain of a small
RING finger protein Rbxl binds to E2, and the F-box protein that binds
via an adaptor protein Skpl recognizes the substrate protein and ubi-
quitinates. MAFbx-1/atrogin-1 is a type of F-box protein and has a
molecular weight of approximately 40 kDa. Many types of ubiquitin
ligases have been reported to bind to other proteins, including neural
precursor cell expressed developmentally down-regulated protein 8
(Nedd8)-ubiquitin-like protein and cullin-associated Nedd8-dissociated
1 (CAND1) [10,11].
2.1. MAFbx-1/atrogin-1
MAFbx-1/atrogin-1 is reported to ubiquitinate and degrade myo-
cardial calcineurin A [12]. In fact, the overexpression of MAFbx-1/
atrogin-1 inhibits calcineurin-mediated myocardial hypertrophy.
However, it remains unclear whether MAFbx-1/atrogin-1 uses calci-
neurin A as a substrate in skeletal muscle. In skeletal muscle, MyoD, a
transcription factor important for muscle cell differentiation and de-
velopment, interacts with MAFbx-1/atrogin-1 [13]. However, the
muscle tissue of MAFbx-1/atrogin-1 deficient mice was found to be
normal. The physiological significance of the binding of MAFbx-1/
atrogin-1 to MyoD remains unknown. In contrast, it has been reported
that the translation system elF3 is a substrate for MAFbx-1/atrogin-1
[14], suggesting it may play an important role in reducing protein
synthesis.
2.2. MuRF-1
MuRF-1 is a 40-kDa monomeric RING-type ubiquitin ligase with an
E2 binding RING domain at the N-terminus and two coiled-coil domains
at the center. Labeit's group identified MuRF-1 as a muscle-specific
protein that binds to the giant muscle constituent protein titin (con-
nectin) at the M-band [15,16]. Therefore, MuRF-1 has been suggested
to be a ubiquitin ligase for the degradation of skeletal muscle con-
stituent proteins. In fact, MuRF-1 has also been reported to ubiquitinate
myosin heavy chains and troponin-1 in skeletal muscle cells and car-
diomyocytes [17]. Interestingly, MuRF-1 was also found to be localized
in the nucleus and bind to glucocorticoid modulatory element binding
protein-1 (GMEB-1), which regulates glucocorticoid-responsive tran-
scription, suggesting that MuRF1 also functions as a transcription factor
co-activator (co-repressor) [19].
3. Cbl-b and its inhibitor Cblin
3.1. Cbl-b and unloading muscle atrophy
Like the oncogene c-Cbl, Cbl-b belongs to the Cbl family of adapter
proteins, which negatively regulate the action of growth factors and
regulate cell differentiation and tissue development. Cbl-b pre-
ferentially interacts with the phosphotyrosine of receptors and in-
tracellular signal molecules and promotes their degradation, thereby
negatively controlling the action of growth factors. Cbl-b is comprised
of a tyrosine kinase binding (TKB) domain at the N-terminal, a RING
domain and proline-rich domain at the center, and a leucine zipper at
the C-terminal. Proteins that bind to Cbl-b are extremely numerous,
although they are not all necessarily ubiquitinated [20].
The ubiquitin ligase Cbl-b plays an important role in skeletal muscle
atrophy induced by unloading as a result of bed-rest or microgravity
[2,5,6]. The mechanism of Cbl-b-induced muscle atrophy is unique and
does not appear to involve the degradation of structural muscle com-
ponents; rather, it impairs muscular trophic signals in response to un-
loading conditions. Recent studies investigating the molecular me-
chanisms of muscle atrophy have found that the role of the IGF-1/
phosphoinositide 3-kinase (PI3K)/Akt-1 signaling cascade is a vital
pathway in the regulation of the balance between hypertrophy and
atrophy [21,22]. These studies suggest that under conditions of muscle
wasting, such as disuse, diabetes, and fasting, a decrease in IGF-1/PI3K/
Akt-1 signaling enhances the expression of atrogin-1, resulting in
muscle atrophy. However, the mechanisms of the unloading-induced
impairment in growth factor signaling were still unknown. In a previous
study, we reported that under both in vitro and in vivo experimental
conditions, Cbl-b ubiquitinated and induced the specific degradation of
IRS-1, a key signaling molecule in skeletal muscle growth, resulting in
the down-regulation of the IGF-1 signaling [2,5]. The down-regulation
of the IGF-1 signaling stimulated the expression of atrogin-1 through
the dephosphorylation (activation) of FOXO3, as well as a reduced
mitogen response in the skeletal muscle. Thus, the natural substrate of
Cbl-b is IRS-1 in skeletal muscle, and the inactivation of Cbl-b is a
beneficial target to prevent muscle atrophy caused by unloading
(Fig. 2).
3.2. Identification of Cblin and Cbl-b inhibitory peptides
A pentapeptide (DGpYMP), corresponding to amino acids 606 to
610 in rat IRS-1, inhibited Cbl-b-mediated IRS-1 ubiquitination and
strongly decreased the Cbl-b-mediated induction of MAFbx-1/atrogin-1
























Fig. 1. Types of ubiquitin ligase (E3). (a) HECT-type ubiquitin ligase, (b) RING
type ubiquitin ligase, (c) U-box-type ubiquitin ligase, and (d) Cullin-type ubi-
quitin ligase.
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Tyrosine-608 of IRS-1 is phosphorylated in response to insulin/IGF-1
[23]. The substitution or dephosphorylation of tyrosine in Cblin failed
to prevent Cbl-b-mediated IRS-1 ubiquitination. The replacement of
tyrosine-608 with phenylalanine in rat IRS-1 also induced resistance to
Cbl-b-mediated ubiquitination. Cblin inhibited the interaction between
Cbl-b and IRS-1 through the phosphotyrosine-608 of IRS-1 (Fig. 2).
Interestingly, tyrosine-608 is a major docking site for PI3K [23,24].
Thus, Cbl-b may compete with PI3K for binding to IRS-1, and functions
as an adapter protein to regulate IGF-1 signaling negatively.
Previous structural and biochemical reports [25,26] indicated that
SDGpYTPEPA, a phosphopeptide of ZAP-70, interacted with the TKB
domain of c-Cbl, which is highly homologous to Cbl-b. Additionally, the
residues that interact with the ZAP-70 peptide [25] are highly
conserved in Cbl ligases. Interestingly, the ZAP-70 peptide very re-
sembled to Cblin. Using the complex structure of the c-Cbl and ZAP-70
peptide as the template, the homology modeling of the Cbl-b TKB do-
main suggested that the peptide-binding site in the TKB domain was
highly conserved in c-Cbl and Cbl-b ubiquitin ligases. The super-
imposition of the model structure onto the complex structure of c-Cbl
and the ZAP-70 peptide also demonstrated a lack of steric hindrance
between Cbl-b and the ZAP-70 peptide. On the basis of these observa-
tions, it is conceivable that Cbl-b binds to the ZAP-70 peptide and Cblin.
It is likely that Cblin acts as a decoy substrate for IRS-1, since Cblin can
competitively inhibit the binding of Cbl-b to IRS-1.
3.3. Structure of the TKB domain in Cbl-b complexed with Cblin
Nikawa's group determined the structure of the Cbl-b TKB domain
(residues 39–341) co-crystallized with Cblin (refined at 2.5 Å resolu-
tion) [27]. The crystallographic asymmetric unit was found to be
comprised of three TKB molecules (chains A, B, and C), where only
chain B was bound to Cblin. The binding of Cblin to the TKB domain
caused a conformational change, resulting in decreased ubiquitin ligase
activity. Upon binding to Cblin, the SH2 domain was found to move
closer to the 4H domain; this change was previously reported for other
substrate-derived phosphopeptide-TKB complexes [27]. The important
interaction between Cbl-b and Cblin is the insertion of the phosphory-
lated tyrosine residue (pY) on Cblin into a positively charged pocket of
the Cbl-b TKB domain. This positively charged pocket, which is formed
by the residues in the BC loop of the SH2 domain and the AB loop of the
4H domain (Fig. 3), is one of the binding pockets of Cbl-b for substrates
with pY. In addition, the Cblin-bound form (chain B) of the Cbl-b TKB
domain was similar to the same domain complexed with EGFR- and
Zap-70-derived phosphopeptides [28].
The detail interactions (hydrogen bonds and van der Waals inter-
actions) between the Cbl-b TKB domain and Cblin were analyzed using
LIGPLOT [29]. The interactions were found to be primarily mediated by
11 hydrogen bonds. The pY of Cblin had six hydrogen-bonds interacting
with four residues of the SH2 domain (Arg-286, Ser-288, Cys-289, and
Thr-290). Furthermore, the phosphate group of pY formed a water-
mediated hydrogen bond with the carbonyl oxygen of Pro-71 on the 4H
domain. This water molecule also made hydrogen bonds with the ni-
trogen backbone of Tyr-266 in the SH2 domain of the Cbl-b TKB do-
main. Only three additional hydrogen bonds, not involving the pY, were
formed between the TKB domain and Cblin residues, suggesting that pY
on Cblin is important for its interaction with the Cbl-b TKB domain.
3.4. Modification of the Cblin peptide
Being a pentapeptide, Cblin is easily degraded by aminopeptidase in
sera and is difficult to incorporate into the cells. To improve these
Fig. 2. Mechanistic model of unloading-mediated muscle atrophy. This figure is
reproduced from Fig. 7 in Nakao's paper [5] with slight modifications. Un-
loading induces ubiquitin ligase Cbl-b in myocytes Cbl-b stimulates ubiquiti-
nation and the degradation of IRS-1, resulting in IGF-1 resistance in myocytes
during unloading. IGF-1 resistance impairs protein synthesis and enhances
protein degradation in muscles, resulting in muscle atrophy. Cbl-b and PI3K
may competitively interact with IRS-1 at its phosphotyrosine-608. The inhibi-
tion of Cbl-b and IRS-1 interaction by Cblin and Cblin-like peptides may restore
this impairment of IGF-1 signaling. GSK3, glycogen synthase kinase 3; mTOR,
mammalian target of rapamycin; S6K, p70 S6 kinase; Ub, ubiquitin.
Fig. 3. Crystal structure of the Cbl-b TKB
domain complexed with Cblin. This figure is
taken from Fig. 2 in Ohno's study [27]. (a)
Ribbon representation of the Cbl-b TKB do-
main, with Cblin in stick form. The green,
yellow, and orange regions denote the 4H
domain, EF-hand domain, and SH2 domain,
respectively. (b) Electrostatic surface po-
tential of the Cbl-b TKB domain (white,
blue, and red contours are neutral, positive,
and negative, respectively,). Cblin is shown
in stick form. The yellow dotted circle in-
dicates the phosphate group of Cblin.
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characteristics, we myristoylated the N-termini of the Cblin peptide
(C14-Cblin). As expected, N-myristylation increased the permeability of
Cblin into the cells about 10-fold, in addition to the resistance against
aminopeptidase [7]. When Cblin and C14-Cblin were applied simulta-
neously to HEK293 cells at the same concentration (50 nmol/dish), the
amount of incorporated Cblin and C14-Cblin was 0.30 and 3.6 nmol,
respectively. Lastly, the increased permeability of Cblin led to an en-
hanced inhibition of Cbl-b-mediated IRS-1 ubiquitination [7]. Both
Cblin and C14-Cblin similarly and effectively inhibited IRS-1 ubiquiti-
nation by Cbl-b in the cell-free ubiquitination assay. However, in an-
other ubiquitination inhibitory assay using Cbl-b- and IRS-1-transfected
HEK293 cells, C14-Cblin more effectively inhibited Cbl-b-mediated IRS-
1 ubiquitination than Cblin. The concentrations for 50% inhibitory ef-
ficacy (IC50) of Cblin and C14-Cblin were 120 and 30 μM, respectively.
3.5. Cblin-like peptide in soy glycinin
As described above, Cblin (DGpYMP) inhibited Cbl-b-mediated
ubiquitination and degradation of IRS-1 both in vitro and in vivo [5,7].
We investigated proteins containing a Cblin-like sequence using the
Basic Local Alignment Search Tool (http://blast.ncbi.nlm.nih.gov/
Blast.cgi/) and discovered that soy glycinin in soy protein contains a
sequence similar to that of Cblin peptide, DI/FYNP. Multiple sequence
alignments of five soy glycinin homologs, G1, G2, G3, G4, and G, in-
dicated that this sequence, DIYNP, is conserved among these glycinin
homologs (Fig. 4) [8]. Since this phosphorylated peptide, DIpYNP, also
showed inhibitory activity against Cbl-b-mediated IRS-1 ubiquitination
with an IC50 of 350 μM, we called this phosphorylated peptide Cblin-
like peptide.
To evaluate the inhibitory effects of dietary soy glycinin on Cbl-b-
mediated muscle atrophy in vivo, we administered the four following
diets to denervated mice: 20% casein diet (control diet), 20% soy
protein isolate (SPI) diet (similar to about 6% glycinin diet), 10% gly-
cinin diet, and 20% glycinin diet [8]. There were no significant dif-
ferences in the daily intake of food, protein, and energy among the four
groups of mice. Denervation for 4 days significantly decreased the
cross-sectional area (CSA) of the TA muscle in the control diet group
(Fig. 5). Interestingly, the glycinin diet improved this decrease in CSA
in proportion to the content of glycinin in the diet. Feeding with 20%
soy glycinin diet significantly broadened the CSA distribution compared
to mice on the SPI diet and the 10% soy glycinin +10% casein diet
groups. Several studies have found that soy protein is beneficial for
preventing muscle damage and muscle protein catabolism after exercise
[30,31]. Cblin-like peptides in soy protein may partially contribute to
this beneficial effect.
4. Discussion
There is currently no effective drug or food for the prevention of
unloading-mediated muscle atrophy. When we first began researching
proteases and their inhibitors in Professor Katunuma's lab, he insisted
on the importance of developing a useful drug, as well as elucidating
the mechanisms of diseases, a philosophy that we have since respected.
Therefore, our aim is to develop Cbl-b inhibitors with small mole-
cular weights (i.e., drugs) against unloading-mediated muscle atrophy.
Based on the crystallographic analysis of the complex of Cbl-b TKB
domain and Cblin, we are developing chemical Cbl-b inhibitors for use
as therapeutic drugs for the treatment and prevention of muscle
atrophy.
Because of our expertise in the field of nutrition, we are also in-
terested in functional peptides. Functional peptides are food-derived
peptides of nutritional value that exert physiological and hormone-like
effects in humans [32]. Functional peptides are inactive within the
sequence of their parent protein and can be released by enzymatic
hydrolysis during either gastrointestinal digestion or food processing.
They are found in milk, egg, meat, and various kinds of fish, as well as
in many plants [32]. Since an amino acid sequence similar to Cblin in
soy glycinin was found to inhibit the denervation-mediated ubiquiti-
nation of IRS-1, this sequence of soy is likely to be a potent functional
peptide against muscle atrophy [8]. Unlike various types of medicine,
food-derived peptides have few side effects. Based on this property,
dietary soy protein is a suitable source of protein for the efficient
control of muscle protein catabolism.
However, controversy remains surrounding the detection of food-
derived bioactive peptides, unlike other functional substances, such as
polyphenols and polyamines. Some peptides found in foods with in vitro
biological activity may be further degraded by peptidases during the
process of ingestion, digestion, and absorption. In addition, peptides are
difficult to absorb in the intestine or other organs. Consequently, these
peptides may lose their potential activity when detected based on their
Fig. 4. Amino acid sequence of soy glycinin. This figure is reproduced from Fig. 1 in Abe's paper [8] with modifications. Almost all soy glycinins contain a Cblin-like
sequence.
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biological activity. Therefore, the modification of peptides, such as by
N-myristylation, may be necessary to fully harness their function. In
general, N-myristylation is mediated by fermentation [33]. The fer-
mentation of foods allows for an increase in the permeability and sta-
bility of dietary functional peptides.
5. Conclusions
Protease inhibitors are used to treat disused muscle atrophy. Muscle
protein degradation increases when muscles are unused under various
conditions. In this review, we summarized the structures and functions
of ubiquitin ligases associated with muscle atrophy. In particular, the
peptide structure-based inhibitors of Cbl-b showed potential as seed
compounds for use in medical applications in the future. The Cblin
peptide and its derivatives suppress the ubiquitination of IRS-1, a key
adapter protein in the IGF-1 signaling pathway, in cell-free ubiquiti-
nation assays. The Cblin-like peptide of soy glycinin also suppresses the
ubiquitination of IRS-1 in IGF-I-treated HEK293 cells transfected with
the expression vectors for Cbl-b, IRS-1, and ubiquitin. Furthermore, soy
glycinin-enriched diets affect denervation-induced muscle atrophy. In
conclusion, these peptide-based Cbl-b inhibitors represent promising
therapeutic strategies for the treatment of muscle atrophy induced
under various circumstances, such as in bedridden patients.
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